Brokerages Set Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Target Price at $21.00

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have received a consensus rating of “Buy” from the six ratings firms that are covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $21.00.

Separately, HC Wainwright began coverage on Artiva Biotherapeutics in a research report on Monday, December 30th. They set a “buy” rating and a $20.00 price objective for the company.

Artiva Biotherapeutics Stock Performance

NASDAQ:ARTV opened at $5.87 on Friday. Artiva Biotherapeutics has a 52 week low of $3.37 and a 52 week high of $17.31. The company has a fifty day simple moving average of $5.50 and a two-hundred day simple moving average of $9.68.

Institutional Trading of Artiva Biotherapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets acquired a new stake in Artiva Biotherapeutics during the third quarter worth approximately $42,000. China Universal Asset Management Co. Ltd. acquired a new stake in Artiva Biotherapeutics during the 4th quarter worth $52,000. Wells Fargo & Company MN raised its stake in Artiva Biotherapeutics by 64.0% during the 4th quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock worth $87,000 after acquiring an additional 3,361 shares in the last quarter. MetLife Investment Management LLC purchased a new stake in Artiva Biotherapeutics in the third quarter valued at $135,000. Finally, JPMorgan Chase & Co. acquired a new position in Artiva Biotherapeutics in the third quarter valued at $166,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.